Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

“Should we have an RSV vaccine for older Australians? Absolutely. We have two highly effective vaccines, one made by GSK, one made by Pfizer, which are being implemented and used widely now in ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...